JPMorgan Chase & Co. Sells 9,681,000 Shares of Repligen Co. (NASDAQ:RGEN)

JPMorgan Chase & Co. cut its holdings in Repligen Co. (NASDAQ:RGEN) by 96.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 363,499 shares of the biotechnology company’s stock after selling 9,681,000 shares during the period. JPMorgan Chase & Co.’s holdings in Repligen were worth $54,096,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in RGEN. Andra AP fonden bought a new stake in shares of Repligen in the 2nd quarter valued at approximately $25,000. UMB Bank n.a. raised its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the period. Blue Trust Inc. lifted its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new position in Repligen during the third quarter worth $37,000. Finally, Quarry LP increased its position in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 4.8 %

NASDAQ:RGEN opened at $149.90 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a 50-day simple moving average of $144.96 and a 200-day simple moving average of $142.20. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm has a market cap of $8.40 billion, a P/E ratio of -405.12, a P/E/G ratio of 4.64 and a beta of 0.97.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the prior year, the business earned $0.23 earnings per share. Repligen’s revenue was up 9.7% on a year-over-year basis. Equities analysts anticipate that Repligen Co. will post 1.54 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday. Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $185.20.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.